Pharma Tech

Merck KGaA-backed Cyllene Therapeutics secures €33m for gene therapy pipeline

Jul 7, 2026, 2:31 PM

Read Full Article → Merck KGaA-backed Cyllene Therapeutics secures €33m for gene therapy pipeline

Translate article text

Choose a language and wait for the translated text.

Fresh with a rebrand, Cyllene will advance gene therapies built on a platform that uses a modified form of the herpes virus for delivery.